Any content you receive is for information purposes only. Always conduct your own research.*Sponsored by Nutriband Inc.
Jeff Ackerman Puts (NTRB) Back At The Top Of This Morning's Watchlist—Monday, December 29, 2025
Don't Miss The Next Breakout—Get Real-Time Alerts Sent Directly
To Your Phone. Up To 10X Faster Than Email.
Full Coverage is Starting Right Now
Pull Up (NTRB) Before The Bell Rings…
December 29 2025
Morning Trend Watch | Why (NTRB) is Rising on Our Watchlist Ahead of the Bell Dear Reader, Some companies move in silence until the story becomes too big to ignore. When the mission lines up with the moment—and federal priorities start shifting in the same direction—that's when the spotlight changes fast. And right now, few stories are aligning like this one. That's why Nutriband Inc. (NASDAQ: NTRB) is topping our watchlist this morning— Monday, December 29, 2025.
But keep in mind, (NTRB) has less than 5M shares listed in its float according to MarketWatch. When floats are this small, the potential exists for big moves if demand begins to shift. Recently, Robert LeBoyer, Senior Vice President and Biotechnology Analyst at Noble Capital Markets, reiterated his $15 target on the company—which suggests over 230% upside potential from recent $4.50 levels. 
And it's not just because of the charts. On Dec. 18, (NTRB) issued a statement responding to the U.S. Executive Order targeting illicit fen-tan-yl, drawing a clear line between illegal fen-tan-yl and FDA-regulated prescription therapies—while underscoring the urgent need for safer transdermal patches to reduce misuse and accidental exposure. 
That same day, the company also signed a non-binding LOI with the Qvanta Group of Companies, an advanced technology organization developing quantum-ready AI infrastructure, to explore secure AI analytics and simulation tools that could support regulated pharmaceutical innovation tied to abuse-deterrent development. And adding to the momentum, (NTRB) recently announced that Co-Founder Gareth Sheridan has returned as Chief Executive Officer, stepping back in to guide the company through the final stretch toward its 2026 NDA filing for AVERSA™ Fen-tan-yl. Sheridan's return restores founding leadership at a pivotal moment, as (NTRB) moves closer to what could become the world's first FDA-approved abuse-deterrent opioid patch. The company projects peak U.S. sales potential of $80M–$200M, with plans to expand access across major global healthcare markets. Nutriband Inc. (NASDAQ: NTRB) is a transdermal pharmaceutical company developing its proprietary AVERSA™ abuse-deterrent technology, designed to make commonly misused pain patches significantly harder to abuse while improving safety and patient comfort. Rather than creating new chemical compounds, (NTRB) enhances existing FDA-approved dr-ugs by embedding its patented deterrent layers into proven transdermal delivery systems. Under Sheridan's renewed leadership, (NTRB) continues to operate with a structure built for both innovation and sustainability. The company has three wholly owned subsidiaries—4P Therapeutics, Pocono Pharmaceuticals, and Active Intelligence—that collectively generate revenue and help offset research and development costs. - 4P Therapeutics manages Nutriband's clinical and regulatory programs.
- Pocono Pharmaceuticals provides contract manufacturing for clients ranging from small firms to global consumer brands like Reebok and KT Tape.
- Active Intelligence produces kinesiology and consumer health products, including a vitamin-based mosquito-repellent patch already approved for sale in Central America.
This diversified foundation provides operational stability and financial discipline, allowing (NTRB) to advance its pharmaceutical pipeline without constantly relying on new capital raises—an approach management believes helps preserve long-term shareholder value and minimize dilution. Lead Program: AVERSA Fen-tan-yl
(NTRB)'s lead focus, AVERSA Fen-tan-yl, aims to make powerful pain relief safer by preventing patch misuse and accidental exposure. The patch includes a protective layer made from harmless but highly unpleasant ingredients—deterrents that make tampering nearly impossible. To prepare for commercialization, (NTRB) partnered with Kindeva Dr-ug Delivery, a global leader in transdermal manufacturing, to complete large-scale production. This milestone confirms the company's ability to produce commercial-ready batches and move toward final testing. The next major step is a human study comparing AVERSA Fen-tan-yl with standard patches to measure resistance to tampering or extraction. Following FDA meetings in September 2025, (NTRB) expects the study to begin in early 2026, with an FDA submission later in the year and potential approval by late 2026 or 2027. Adding to this progress, (NTRB) signed an agreement on October 10, 2025, with Brand Institute, Inc., the world leader in dr-ug naming and identity development, to create the official brand name and visual identity for AVERSA™ Fen-tan-yl—another signal that commercial readiness is near. Market Outlook and Sales Potential
A study commissioned by Advanced Health estimated that AVERSA Fen-tan-yl could bring in around $200M in annual sales after launch. If regulators decide that all pain patches must include similar safety technology—something that's possible once AVERSA proves its value—sales could grow toward $800M a year. The same analysis also suggested that insurers may pay about 20% more for a safer, branded patch because it lowers the risk of patient harm and accidental exposure. This potential comes at a time when many doctors have scaled back on prescribing Fen-tan-yl patches due to misuse concerns, leaving some chronic-pain patients with fewer options. (NTRB)'s solution could help restore confidence among physicians and insurers by offering a patch that provides the same relief but with far fewer safety risks. Intellectual Property and Platform Expansion
(NTRB) has built a strong foundation of patents that protect its technology in more than 45 countries, and new filings are expected to extend that protection until 2045. The company doesn't view AVERSA as just one product—it's a platform that can be applied to other medications that face similar risks of misuse. Next in line are two related patches: - AVERSA Buprenorphine, aimed at treating opioid dependence and chronic pain.
- AVERSA Methylphenidate, designed for attention-deficit disorders.
Because the AVERSA system has already been proven, these follow-on products should move through development much faster—possibly within 6–12 months of the Fen-tan-yl patch approval. Looking further ahead, (NTRB)'s team is also researching a needle-free insulin patch for people with type 2 diabetes. While still early in development, it shows how the same transdermal technology could eventually reach beyond pain management. Near-Term Milestones
Over the next 12 to 18 months, (NTRB)'s progress will center around a few key steps: - Receiving formal FDA feedback from the September 2025 meeting.
- Launching the human abuse study in early 2026 and reviewing results within about three months.
- Preparing the FDA filing later in 2026 with manufacturing data from Kindeva.
- Beginning work on the next AVERSA-based patches for buprenorphine and methylphenidate.
Together, these milestones make 2026 a potentially defining year for (NTRB)—one that could move the company from research mode to full commercial readiness. 7 Reasons Why (NTRB) Just Hit Our Radar This Morning
—Monday, December 29, 2025
1. Limited Float: With less than 5M shares listed as being available to the public, (NTRB)'s small float has the potential to witness big moves if demand begins to shift. 2. Analyst Target: With Noble Capital Markets reiterating a $15 target, (NTRB) has a widely watched reference point that suggests over 230% upside potential from recent $4.50 levels and keeps it front-and-center for many active market participants. 3. Federal Spotlight: After responding to a U.S. Executive Order focused on illicit fen-tan-yl, (NTRB) highlighted the growing need for safer prescription patch solutions that reduce misuse risk. 4. AI Optionality: By signing a non-binding LOI with Qvanta to explore secure AI analytics and simulation tools, (NTRB) introduced a forward-looking layer of innovation tied to regulated pharmaceutical development. 5. Founder Return: With Co-Founder Gareth Sheridan back as CEO, (NTRB) has restored founding leadership as it moves toward major 2026 regulatory milestones. 6. Commercial Readiness: After completing scale-up work with Kindeva and signing Brand Institute for naming and identity development, (NTRB) is showing multiple signs of preparation for the next stage. 7. Potential Catalysts Ahead: With a human study expected in early 2026 and a planned filing later in the year, (NTRB) has a clearly defined timeline that could keep news flow active. Pull Up (NTRB) Before The Bell Rings…
When you step back and connect the dots, it becomes clear why attention around (NTRB) is building. With less than 5M shares listed as being available to the public, even small shifts in demand can create sharp reactions — and that dynamic becomes even more notable when the company is backed by a widely watched analyst view. Noble Capital Markets recently reiterated a $15 target, which suggests over 230% upside potential from recent $4.50 levels, putting (NTRB) firmly on the screen for active market participants. Add in the federal spotlight on safer prescription patch solutions, a forward-looking LOI exploring secure AI and simulation tools, and the return of Co-Founder Gareth Sheridan to guide the company through its 2026 roadmap, and this story starts to look more structured than speculative. With manufacturing scale-up progress completed, naming work underway, and a clear clinical and regulatory timeline ahead, (NTRB) has multiple catalysts that could keep news flow active. We have all eyes on (NTRB) right now. Take a look at (NTRB) this morning before the bell rings. Also, keep a look out for my next update—it could be here any moment. Sincerely, Jeff Ackerman
Managing Editor
Stock News Trends | 
0 Response to "Morning Trend Watch: Why (NTRB) is Rising on Our Watchlist Ahead of the Bell"
Post a Comment